Free Trial
NASDAQ:BXRX

Baudax Bio (BXRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$3.47
Volume
310,800 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BXRX stock logo

About Baudax Bio Stock (NASDAQ:BXRX)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Baudax Bio (BXRX) Gets a Hold from Noble Financial
Noble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)
Baudax Improves on Q1 Results
Recap: Baudax Bio Q1 Earnings
Why Is Baudax Bio (BXRX) Stock Down 52% Today?
See More Headlines
Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2023
Today
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BXRX
Employees
9
Year Founded
N/A

Profitability

Net Income
$-58,790,000.00
Pretax Margin
-18,950.64%

Debt

Sales & Book Value

Annual Sales
$1.27 million
Book Value
($14.93) per share

Miscellaneous

Free Float
52,408,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
1.57
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Geraldine A. Henwood Ph.D. (Age 72)
    President, CEO & Director
    Comp: $633.25k
  • Mike Choi
    Vice President of Financial Planning & Analysis
  • Ms. Natalie McAndrew (Age 53)
    Consultant & Principle Accounting Officer
  • Dr. Chan Kim Yong Ph.D. (Age 50)
    Chief Scientific Officer & Director

BXRX Stock Analysis - Frequently Asked Questions

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) posted its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.55.

When did Baudax Bio's stock split?

Shares of Baudax Bio reverse split before market open on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

This page (NASDAQ:BXRX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners